{"abstract": "Despite the enthusiasm of analysts and investors, the rumored acquisition of Bristol-Myers Squibb by Paris-based Sanofi-Aventis is probably a bad idea in the long term, writes Forbes\u2019 Matthew Herper. Such a deal would be a short-term fix that does nothing to address the drug industry\u2019s big problems: a declining pipeline and fewer medicines reaching patients. ", "web_url": "https://dealbook.nytimes.com/2007/02/02/should-bristol-and-sanofi-link-up/", "snippet": "", "lead_paragraph": "Despite the enthusiasm of analysts and investors, the rumored acquisition of Bristol-Myers Squibb by Paris-based Sanofi-Aventis is probably a bad idea in the long term, writes Forbes\u2019 Matthew Herper. Such a deal would be a short-term fix that does nothing to address the drug industry\u2019s big problems: a declining pipeline and fewer medicines reaching patients. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Should Bristol and Sanofi Link Up?", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-02-02T20:16:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/f9214548-94f5-56d6-a0e1-3c19ebe2beb9", "word_count": 321, "uri": "nyt://article/f9214548-94f5-56d6-a0e1-3c19ebe2beb9"}